Jefferies Starts AC Immune SA (ACIU) at Buy

October 18, 2016 8:11 AM EDT
Get Alerts ACIU Hot Sheet
Price: $12.60 -0.4%

Rating Summary:
    3 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade ACIU Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Jefferies initiates coverage on AC Immune SA (NASDAQ: ACIU) with a Buy rating and a price target of $25.00.

Analyst Peter Welford commented, "ACIU may have the broadest Alzheimer's pipeline in biotech, with active & passive therapies targeting both amyloid beta and tau. Crenezumab underpins our NPVs, partnered with Genentech in Phase III with data 2020E. Sentiment towards ACIU may shift on LLY's competing anti-Abeta solanezumab news around YE. ACIU has three other Phase Ib-IIa products for a pipeline providing a multitude of catalysts by 2018E. We are initiating with a Buy rating and $25/share PT."

For an analyst ratings summary and ratings history on AC Immune SA click here. For more ratings news on AC Immune SA click here.

Shares of AC Immune SA closed at $14.43 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities

Jefferies & Co

Add Your Comment